ENVB
Enveric Biosciences Inc
NASDAQ: ENVB · HEALTHCARE · BIOTECHNOLOGY
$2.44
-1.77% today
Updated 2026-06-02
Market cap
$6.63M
P/E ratio
—
P/S ratio
0.08x
EPS (TTM)
$-22.74
Dividend yield
—
52W range
$2 – $18
Volume
4.7M
Enveric Biosciences Inc (ENVB) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-305907.00 | $329928.00 | $-150186.00 | $-65041.00 | $-40666.00 | $-30346.00 | $-24850.00 | $-21632.00 | $-43164.00 | $-3.67M | $-2.70M | $-2.74M | $-2.57M | $-647860.00 | $-3.89M | $-11.46M | $-17.15M | $-14.09M | $-7.73M | $-8.14M |
| Capital expenditures | $15013.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.69M | $3.69M | $4840.00 | $189719.00 | $84331.00 | $44143.00 | $864719.00 | $584165.00 | $5180.00 | $0.00 | $3.00 |
| Depreciation | $37229.00 | — | — | — | — | — | — | — | — | $157941.00 | $1.36M | $3.22M | $2.90M | $2.27M | $120872.00 | $681612.00 | $435201.00 | $408030.00 | $337489.00 | — |
| Stock-based comp | — | — | — | — | — | — | — | — | — | $141910.00 | $1.46M | $7.08M | $1.25M | $586495.00 | $1.98M | $12.60M | $2.62M | $2.15M | $1.56M | $827323.00 |
| Free cash flow | $-320920.00 | $329928.00 | $-150186.00 | $-65041.00 | $-40666.00 | $-30346.00 | $-24850.00 | $-21632.00 | $-43164.00 | $-5.36M | $-6.39M | $-2.75M | $-2.76M | $-732191.00 | $-3.93M | $-12.32M | $-17.73M | $-14.10M | $-7.73M | $-8.14M |
| Investing cash flow | $-15013.00 | $-350188.00 | $1.00M | — | — | — | — | — | — | $-1.51M | $-6.59M | $-808884.00 | $-3.64M | $-284331.00 | $-44143.00 | $2.19M | $-584165.00 | $11667.00 | — | — |
| Financing cash flow | $-773.00 | $373339.00 | $-1.36M | — | $40000.00 | $47451.00 | $8000.00 | $20500.00 | $48000.00 | $6.24M | $8.80M | $7.05M | $2.69M | $560000.00 | $5.53M | $24.90M | $18.18M | $-1.34M | $7.67M | — |
| Dividends paid | — | — | — | — | — | — | — | — | — | — | — | $2.09B | $2.09T | — | — | — | — | — | — | $3.36M |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Frequently asked questions
What is Enveric Biosciences Inc's revenue?
Enveric Biosciences Inc's trailing twelve-month revenue is $35.41M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How much free cash flow does ENVB generate?
ENVB produced $-8.14M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is ENVB's balance sheet healthy?
ENVB holds $4.68M in cash and equivalents against — in long-term debt, on $4.18M of shareholder equity. That debt is best read against the cash flow the business throws off each year.